Clinical trial

The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial)

NCT01137812

Study summary

ClinicalTrials.gov

The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial)

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

4 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Sitagliptin 100 mg Normalized identity: sitagliptin 100 MG View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Canagliflozin 300 mg Normalized identity: canagliflozin 300 MG View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Metformin Normalized identity: metformin View linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Sulphonylurea Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2010-07-01

PhasePHASE3

Conditions

Diabetes Mellitus, Type 2verified · MONDO: type 2 diabetes mellitus

Interventions

Sitagliptin 100 mgDRUG · verified · RxNorm: sitagliptin 100 MG

Canagliflozin 300 mgDRUG · verified · RxNorm: canagliflozin 300 MG

MetforminDRUG · verified · RxNorm: metformin

SulphonylureaDRUG

Sponsors & collaborators

Janssen Research & Development, LLClead sponsor

Mapped research locations

HoustonTexas, United States1 ChicagoIllinois, United States1 Los AngelesCalifornia, United States1 PhiladelphiaPennsylvania, United States1 DallasTexas, United States1 AtlantaGeorgia, United States1 MiamiFlorida, United States1 TorontoOntario, Canada1 San AntonioTexas, United States1 SeoulSouth Korea1 ParisFrance1 PittsburghPennsylvania, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01137812 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.